Prognostic factors after salvage resection for local progression of brain metastases after radiotherapy - Top-Institutions - MDSpire

Prognostic factors after salvage resection for local progression of brain metastases after radiotherapy

  • By

  • Hideyuki Arita

  • Toshiki Ikawa

  • Naoyuki Kanayama

  • Masahiro Morimoto

  • Toru Umehara

  • Hidenori Yoshizawa

  • Yoshinori Kodama

  • Yoshiko Okita

  • Manabu Kinoshita

  • Koji Konishi

  • June 5, 2025

  • 0 min

Share

Top Institutions in Surgery

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neurosurgery
    • Neuro-oncology
    • Radiation Oncology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Neurosurgery
    • Neuro-oncology
    • Radiation Oncology

  • #3

    Dana-Farber/Brigham and Women’s Cancer Center
    Dana-Farber/Brigham and Women’s Cancer Center

    Boston, MA

    Key Differentiators

    • Neuro-oncology
    • Neurosurgery
    • Radiation Oncology

  • #4

    Osaka International Cancer Institute
    Osaka International Cancer Institute

    Osaka, Osaka Prefecture

    Key Differentiators

    • Neurosurgery
    • Neuro-oncology
    • Radiation Oncology

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Neurosurgery
    • Neuro-oncology
    • Radiation Oncology

Original Source(s)

Prognostic factors after salvage resection for local progression of brain metastases after radiotherapy

  • by Hideyuki Arita, Toshiki Ikawa, Naoyuki Kanayama, Masahiro Morimoto, Toru Umehara, Hidenori Yoshizawa, Yoshinori Kodama, Yoshiko Okita, Manabu Kinoshita, Koji Konishi

  • June 5, 2025

Related Content

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication

  • by

  • May 7, 2026

  • 4 min
PET/CT and MRI Model May Help Stratify Prostate Cancer Risk

Retrospective multicenter radiomics study showed moderate to high discrimination in two small external cohorts